NewcelX Releases Updated Presentation Highlighting Collaboration with Eledon
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 20 2026
0mins
NewcelX (NCEL) announced the release of an updated corporate presentation that includes the company's strategic collaboration with Eledon Pharmaceuticals (ELDN) and highlights the advancement of its flagship Type 1 Diabetes program, NCEL-101, as a central pillar of the company's development strategy. The updated presentation outlines the integration of NewcelX's scalable stem-cell-derived islet replacement platform with Eledon's investigational anti-CD40L monoclonal antibody tegoprubart, a targeted immune-modulation therapy designed to prevent immune-mediated transplant rejection. NewcelX believes this combined approach represents a promising strategy to support durable graft survival and advance the development of a potential functional cure for Type 1 Diabetes.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NCEL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NCEL
About NCEL
NewcelX AG, formerly NLS Pharmaceutics AG, is a Switzerland-based company primarily engaged in the biotechnology industry. The Company focuses on the discovery and development of therapies for rare and complex central nervous system (CNS) disorders, including sleep and neurodevelopmental conditions. The Company offers products like Quilience, which is a clinical-stage pharmaceutical compound. It aims to support the treatment of narcolepsy by modulating monoamine neurotransmission and orexin receptor activity. The Company also develops product like Nolazol, a treatment candidate for Attention Deficit Hyperactivity Disorder (ADHD). The Company is a publicly traded company, listing on the NASDAQ.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- FDA Meeting Outcome: NewcelX successfully completed its Type B Pre-IND meeting with the FDA, receiving constructive feedback on the clinical trial pathway for NCEL-101, marking a significant milestone towards a potential functional cure for type 1 diabetes.
- Increased Development Confidence: CEO Ronen Twito stated that the FDA's feedback has strengthened the company's confidence in its development strategy for NCEL-101, indicating a commitment to expedite the therapy into clinical trials to meet urgent patient needs.
- Combination Therapy Potential: Eledon Pharmaceuticals' CEO Dr. David-Alexandre Gros highlighted that the combination of NCEL-101 with their anti-CD40L monoclonal antibody, tegoprubart, aims to achieve durable graft survival and function, potentially offering a scalable treatment option for individuals with type 1 diabetes.
- Clinical Experience Support: With over 100 transplant recipients having used tegoprubart, important safety and immunological insights have been gained, supporting the advancement of NCEL-101 and indicating its potential in clinical applications.
See More
NewcelX Publishes AstroRx® Study Results
- Clinical Trial Success: NewcelX's AstroRx® has successfully completed Phase 1/2a clinical trials in ALS, showcasing its potential for treating chronic demyelinating diseases like multiple sclerosis, further validating the efficacy of the company's stem cell technology platform.
- Key Findings: The study demonstrates that AstroRx® addresses critical barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting oligodendrocyte progenitor cell differentiation into mature oligodendrocytes, indicating its broad therapeutic potential.
- Collaborative Research: This study was developed in collaboration with esteemed institutions such as the Hebrew University of Jerusalem Hadassah Medical School, highlighting NewcelX's collaborative capabilities in stem cell research and its innovative solutions for complex disease treatments.
- Future Development: NewcelX plans to advance its lead candidate NCEL-101, aimed at addressing critical medical needs in type 1 diabetes through stem cell replacement therapy, demonstrating the company's strategic vision in the field of regenerative medicine.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
NewcelX Schedules Pre-IND Meeting with FDA to Advance Type 1 Diabetes Treatment
- Clinical Trial Milestone: NewcelX has submitted a Pre-IND briefing package to the FDA to advance NCEL-101 into First-In-Human clinical trials, marking a significant step in developing innovative treatments for type 1 diabetes, which could greatly enhance patient quality of life.
- Combination Therapy Approach: NCEL-101 is designed to be used in conjunction with Eledon's immunomodulatory agent, tegoprubart, aiming to achieve outcomes comparable to human islet transplantation, and if successful, it could provide a potential functional cure for type 1 diabetes, significantly impacting the market.
- Positive FDA Interaction: CEO Ronen Twito emphasized that the Pre-IND meeting represents a pivotal milestone in the company's commitment to curing type 1 diabetes, reflecting the FDA's support for innovations in this area, which may accelerate the clinical development process.
- Clinical Experience Support: The use of tegoprubart as an immunosuppressive agent in over 100 transplant recipients provides important safety and immunological insights that bolster the feasibility and market potential of advancing NCEL-101.
See More
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
NewcelX Completes Successful FDA Meeting, Advancing Diabetes Treatment
- FDA Meeting Outcome: NewcelX successfully completed its Type B Pre-IND meeting with the FDA, receiving constructive feedback on the clinical trial pathway for NCEL-101, marking a significant milestone towards a potential functional cure for type 1 diabetes.
- Increased Development Confidence: CEO Ronen Twito stated that the FDA's feedback has strengthened the company's confidence in its development strategy for NCEL-101, indicating a commitment to expedite the therapy into clinical trials to meet urgent patient needs.
- Combination Therapy Potential: Eledon Pharmaceuticals' CEO Dr. David-Alexandre Gros highlighted that the combination of NCEL-101 with their anti-CD40L monoclonal antibody, tegoprubart, aims to achieve durable graft survival and function, potentially offering a scalable treatment option for individuals with type 1 diabetes.
- Clinical Experience Support: With over 100 transplant recipients having used tegoprubart, important safety and immunological insights have been gained, supporting the advancement of NCEL-101 and indicating its potential in clinical applications.
See More
NewcelX Publishes AstroRx® Study Results
- Clinical Trial Success: NewcelX's AstroRx® has successfully completed Phase 1/2a clinical trials in ALS, showcasing its potential for treating chronic demyelinating diseases like multiple sclerosis, further validating the efficacy of the company's stem cell technology platform.
- Key Findings: The study demonstrates that AstroRx® addresses critical barriers to remyelination by enhancing myelin debris clearance, sustaining a pro-repair inflammatory environment, and promoting oligodendrocyte progenitor cell differentiation into mature oligodendrocytes, indicating its broad therapeutic potential.
- Collaborative Research: This study was developed in collaboration with esteemed institutions such as the Hebrew University of Jerusalem Hadassah Medical School, highlighting NewcelX's collaborative capabilities in stem cell research and its innovative solutions for complex disease treatments.
- Future Development: NewcelX plans to advance its lead candidate NCEL-101, aimed at addressing critical medical needs in type 1 diabetes through stem cell replacement therapy, demonstrating the company's strategic vision in the field of regenerative medicine.
See More
Tango Therapeutics Shares Surge Over 50% on Positive Trial Data
- Positive Clinical Trial Data: Tango Therapeutics' Vopimetostat shows a 90% six-month progression-free survival rate in its Phase 1/2 trial for pancreatic cancer, prompting plans to advance to Phase 3, thereby enhancing its competitive edge in cancer treatment.
- Aspire Biopharma Growth Prospects: Aspire Biopharma aims to file its NDA for high-dose sublingual aspirin by the end of 2026, and its acquisition of Dura Driver Control Systems is expected to generate over $200 million in revenue, further solidifying its market position.
- Alvotech FDA Application Progress: Alvotech's AVT16 biosimilar application has been accepted for FDA review, which is anticipated to significantly bolster its competitive stance in the biopharmaceutical market, particularly for treating Crohn's disease and ulcerative colitis.
- Zevra Patent Protection Enhancement: Zevra Therapeutics' MIPLYFFA has been listed in the Orange Book by the U.S. Patent Office, with patent protection extending to 2041, expected to significantly enhance its exclusivity and revenue potential in the rare disease market.
See More
NewcelX Schedules Pre-IND Meeting with FDA to Advance Type 1 Diabetes Treatment
- Clinical Trial Milestone: NewcelX has submitted a Pre-IND briefing package to the FDA to advance NCEL-101 into First-In-Human clinical trials, marking a significant step in developing innovative treatments for type 1 diabetes, which could greatly enhance patient quality of life.
- Combination Therapy Approach: NCEL-101 is designed to be used in conjunction with Eledon's immunomodulatory agent, tegoprubart, aiming to achieve outcomes comparable to human islet transplantation, and if successful, it could provide a potential functional cure for type 1 diabetes, significantly impacting the market.
- Positive FDA Interaction: CEO Ronen Twito emphasized that the Pre-IND meeting represents a pivotal milestone in the company's commitment to curing type 1 diabetes, reflecting the FDA's support for innovations in this area, which may accelerate the clinical development process.
- Clinical Experience Support: The use of tegoprubart as an immunosuppressive agent in over 100 transplant recipients provides important safety and immunological insights that bolster the feasibility and market potential of advancing NCEL-101.
See More
NLS Pharmaceutics Reports FY 2025 Financial Results
- Financial Overview: NLS Pharmaceutics reported a GAAP EPS of -$2.16 for FY 2025, indicating ongoing financial losses that reflect the company's pressures and challenges in market competition.
- Cash Position: As of December 31, 2025, the company had $2.2 million in cash and cash equivalents, suggesting a tight liquidity situation that may impact future operational and investment decisions.
- Net Loss Breakdown: The net loss for 2025 was $8.3 million, including $5.7 million in non-cash accounting-related finance expenses primarily linked to the fair value remeasurement of convertible instruments, which are not expected to recur, potentially improving future financial conditions.
- Operating Cash Flow: The net cash used in operating activities was $2.8 million, reflecting increased investments in NCEL-101 development activities, which, while increasing short-term financial pressure, may enhance product development and market competitiveness in the long run.
See More
NewcelX Collaborates with Eledon to Advance Diabetes Treatment
- Strategic Collaboration Highlight: NewcelX's partnership with Eledon Pharmaceuticals integrates its stem-cell-derived islet replacement platform with Eledon's immune modulation therapy, aiming to enhance treatment success rates and provide patients with more durable graft survival.
- Core Program Advancement: NCEL-101, NewcelX's flagship program, focuses on restoring insulin production through scalable cell replacement therapy, marking a strategic emphasis in diabetes treatment that is expected to significantly improve patient quality of life.
- Industry Presentation Plans: NewcelX plans to showcase its updated corporate presentation at the upcoming Swiss Biotech Conference, emphasizing its development vision for the diabetes program to attract more investment and collaboration opportunities.
- Forward-Looking Statements: The company notes in its press release that while the collaboration appears promising, it faces multiple uncertainties related to technology, market conditions, and regulatory approvals that could impact the progress of clinical trials and market acceptance of its products.
See More
